Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AGS-500
- Development stage
- Preclinical
- Lead developer
- Neuromagen Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AGS-500 is a small molecule telomerase activator being developed by Neuromagen Pharma. It functions by stimulating the activity of Telomerase Reverse Transcriptase (TERT), the catalytic subunit of the telomerase enzyme. By enhancing telomerase activity, AGS-500 aims to counteract cellular senescence and promote tissue regeneration. The drug is currently in preclinical development (in vivo efficacy stage) for a variety of indications, including neurodegenerative diseases like Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as Type 1 Diabetes, fertility issues, and conditions related to skin and hair health.
02
Targets
TERT (Telomerase)
Beyond the preview
Go deeper on AGS-500.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AGS-500.